Severing the peptide linker triggers the release of paclitaxel outside the cancer cells. The free drug then enters the cells by passive diffusion with no loss of potency. According to the researchers, this type of treatment could be therapeutically active against a large variety of tumor types.
Understanding the inflammation-cancer transformation in the development of primary liver cancer
Please note that to comment on an article you must be registered and logged in. Registration is for free, you may already be registered to receive, e. All comments are subject to moderation. Search Wiley Online Library.
If you would like to reuse any content , in print or online, from ChemistryViews. A product of and Wiley-VCH.
Passar bra ihop
DOI : Background: ILA is a founding member of the IL family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, ILA participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, ILA dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. ILA has emerged as a topic of interest and is under profound investigation for its involvement in several types of inflammatory-associated diseases.
Mediators of Inflammation
Objective: This review aims to present an overview of the state of the art of ILA role in cancer and inflammation, as well as to describe recent patents targeting ILA with relevant clinical and biological properties for the prevention and treatment of cancer and inflammatory diseases. Methods: Relevant information was obtained by searching in PubMed using ILA or IL, cancer and inflammation as keywords, while relevant patents were obtained mainly from Google Patents.
Results: Literature data indicated ILA as important biomolecule in the physiopathology of cancer and inflammatory diseases. Whereas, novel patents to targeting ILA are focused mainly on describing strategies to modulate ILA per se, co-modulation by bispecific antibodies to blocking ILA and important cytokines for ILA functions, upstream mechanisms and compounds to regulate ILA expression.
Conclusion: The promising effects of patented agents against ILA may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases. Subotica 4, Belgrade.
Abstract: Background: ILA is a founding member of the IL family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. Juan F.